Evidence check: CYP2C19 in the context of Schlaf

CYP2C19 is a cytochrome P450 enzyme primarily involved in metabolizing drugs such as clopidogrel, proton pump inhibitors, and some antidepressants (e.g., citalopram). In the context of sleep, CYP2C19 does not have a strong, direct genetic association. The link is indirect: variants in CYP2C19 can affect the metabolism of certain sleep medications (e.g., diazepam, which is partially metabolized by CYP2C19) or antidepressants that influence sleep. However, evidence for a standalone effect on sleep quality, latency, or architecture is weak. No major GWAS have identified CYP2C19 as a primary factor for sleep traits. Clinical relevance is limited to personalized drug dosing, not to natural sleep propensity or disorders. A CYP2C19 genetic test therefore does not predict your sleep patterns. Evidence: mechanistic, based on enzyme function and pharmacokinetics. Caveat: No direct sleep association; interpretation only meaningful in the context of medication therapy.